The first clinical trial of antioxidant, carvedilol-eluting stent in coronary artery diseases

Weon Kim, Myung Ho Jeong, Sang Yeob Lim, Sang Rok Lee, Kye Hun Kim, Il Suk Sohn, Hyung Wook Park, Young Jun Hong, Ju Han Kim, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and Objectives: Carvedilol is a beta- and alpha-receptor blocker, a direct inhibitor of smooth muscle cell proliferation and migration, and it produced a significant suppression of neointimal hyperplasia in our porcine experiment. The purpose of the study was to investigate the safety and efficacy of carvedilol-eluting BiodiVysio stent implantation for de novo lesions. Subjects and Methods: We performed a prospective randomized trial to compare two types of stents for revascularization in 39 patients [Group I (carvedilol-eluting stent): n = 20, 58.3 ± 11.1 years, and Group II (control stent): n = 19, 59.9 ± 8.5 years]. The primary effective end points were major adverse cardiac events (MACE): cardiac death, acute myocardial infarction, target lesion revascularization (TLR), in-stent restenosis and late lumen loss at the one-year clinical and angiographic follow-up. Results: All the stents were successfully deployed and the patients were discharged without experiencing any clinical events. The baseline clinical characteristics, baseline diameter stenosis and minimal luminal diameter were not different between the two groups. The follow-up diameter stenosis and late loss were significantly lower in the group I compared with group II (23.1 ± 12.7% vs. 47.3 ± 23.6%, p = 0.012; and 0.52 ± 0.26 mm vs. 1.12 ± 0.67 mm; p = 0.020, respectively). There were no TLR and MACE in group I; however the differences were not significant [0% (0/20) vs. 10.5% (2/19); p = 0.231 and 0% (0/20) vs. 15.8% (3/19), p = 0.106, respectively]. Conclusion: Carvedilol-eluting stents appear feasible to use and they may be effective in the prevention of coronary restenosis. These results warrant further confirmation with a large, randomized multi-center trial.

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalKorean Circulation Journal
Volume36
Issue number2
Publication statusPublished - 2006 Feb 1
Externally publishedYes

Fingerprint

Stents
Coronary Artery Disease
Antioxidants
Clinical Trials
Pathologic Constriction
Coronary Restenosis
carvedilol
Smooth Muscle Myocytes
Cell Movement
Hyperplasia
Swine
Myocardial Infarction
Cell Proliferation
Safety
Control Groups

Keywords

  • Antioxidants
  • Coronary disease
  • Coronary restenosis
  • Stents

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, W., Jeong, M. H., Lim, S. Y., Lee, S. R., Kim, K. H., Sohn, I. S., ... Kang, J. C. (2006). The first clinical trial of antioxidant, carvedilol-eluting stent in coronary artery diseases. Korean Circulation Journal, 36(2), 115-120.

The first clinical trial of antioxidant, carvedilol-eluting stent in coronary artery diseases. / Kim, Weon; Jeong, Myung Ho; Lim, Sang Yeob; Lee, Sang Rok; Kim, Kye Hun; Sohn, Il Suk; Park, Hyung Wook; Hong, Young Jun; Kim, Ju Han; Ahn, Young Keun; Cho, Jeong Gwan; Park, Jong Chun; Kang, Jung Chaee.

In: Korean Circulation Journal, Vol. 36, No. 2, 01.02.2006, p. 115-120.

Research output: Contribution to journalArticle

Kim, W, Jeong, MH, Lim, SY, Lee, SR, Kim, KH, Sohn, IS, Park, HW, Hong, YJ, Kim, JH, Ahn, YK, Cho, JG, Park, JC & Kang, JC 2006, 'The first clinical trial of antioxidant, carvedilol-eluting stent in coronary artery diseases', Korean Circulation Journal, vol. 36, no. 2, pp. 115-120.
Kim, Weon ; Jeong, Myung Ho ; Lim, Sang Yeob ; Lee, Sang Rok ; Kim, Kye Hun ; Sohn, Il Suk ; Park, Hyung Wook ; Hong, Young Jun ; Kim, Ju Han ; Ahn, Young Keun ; Cho, Jeong Gwan ; Park, Jong Chun ; Kang, Jung Chaee. / The first clinical trial of antioxidant, carvedilol-eluting stent in coronary artery diseases. In: Korean Circulation Journal. 2006 ; Vol. 36, No. 2. pp. 115-120.
@article{b1ea261ee2cd4dc18c3886d02fc1fca6,
title = "The first clinical trial of antioxidant, carvedilol-eluting stent in coronary artery diseases",
abstract = "Background and Objectives: Carvedilol is a beta- and alpha-receptor blocker, a direct inhibitor of smooth muscle cell proliferation and migration, and it produced a significant suppression of neointimal hyperplasia in our porcine experiment. The purpose of the study was to investigate the safety and efficacy of carvedilol-eluting BiodiVysio stent implantation for de novo lesions. Subjects and Methods: We performed a prospective randomized trial to compare two types of stents for revascularization in 39 patients [Group I (carvedilol-eluting stent): n = 20, 58.3 ± 11.1 years, and Group II (control stent): n = 19, 59.9 ± 8.5 years]. The primary effective end points were major adverse cardiac events (MACE): cardiac death, acute myocardial infarction, target lesion revascularization (TLR), in-stent restenosis and late lumen loss at the one-year clinical and angiographic follow-up. Results: All the stents were successfully deployed and the patients were discharged without experiencing any clinical events. The baseline clinical characteristics, baseline diameter stenosis and minimal luminal diameter were not different between the two groups. The follow-up diameter stenosis and late loss were significantly lower in the group I compared with group II (23.1 ± 12.7{\%} vs. 47.3 ± 23.6{\%}, p = 0.012; and 0.52 ± 0.26 mm vs. 1.12 ± 0.67 mm; p = 0.020, respectively). There were no TLR and MACE in group I; however the differences were not significant [0{\%} (0/20) vs. 10.5{\%} (2/19); p = 0.231 and 0{\%} (0/20) vs. 15.8{\%} (3/19), p = 0.106, respectively]. Conclusion: Carvedilol-eluting stents appear feasible to use and they may be effective in the prevention of coronary restenosis. These results warrant further confirmation with a large, randomized multi-center trial.",
keywords = "Antioxidants, Coronary disease, Coronary restenosis, Stents",
author = "Weon Kim and Jeong, {Myung Ho} and Lim, {Sang Yeob} and Lee, {Sang Rok} and Kim, {Kye Hun} and Sohn, {Il Suk} and Park, {Hyung Wook} and Hong, {Young Jun} and Kim, {Ju Han} and Ahn, {Young Keun} and Cho, {Jeong Gwan} and Park, {Jong Chun} and Kang, {Jung Chaee}",
year = "2006",
month = "2",
day = "1",
language = "English",
volume = "36",
pages = "115--120",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "2",

}

TY - JOUR

T1 - The first clinical trial of antioxidant, carvedilol-eluting stent in coronary artery diseases

AU - Kim, Weon

AU - Jeong, Myung Ho

AU - Lim, Sang Yeob

AU - Lee, Sang Rok

AU - Kim, Kye Hun

AU - Sohn, Il Suk

AU - Park, Hyung Wook

AU - Hong, Young Jun

AU - Kim, Ju Han

AU - Ahn, Young Keun

AU - Cho, Jeong Gwan

AU - Park, Jong Chun

AU - Kang, Jung Chaee

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Background and Objectives: Carvedilol is a beta- and alpha-receptor blocker, a direct inhibitor of smooth muscle cell proliferation and migration, and it produced a significant suppression of neointimal hyperplasia in our porcine experiment. The purpose of the study was to investigate the safety and efficacy of carvedilol-eluting BiodiVysio stent implantation for de novo lesions. Subjects and Methods: We performed a prospective randomized trial to compare two types of stents for revascularization in 39 patients [Group I (carvedilol-eluting stent): n = 20, 58.3 ± 11.1 years, and Group II (control stent): n = 19, 59.9 ± 8.5 years]. The primary effective end points were major adverse cardiac events (MACE): cardiac death, acute myocardial infarction, target lesion revascularization (TLR), in-stent restenosis and late lumen loss at the one-year clinical and angiographic follow-up. Results: All the stents were successfully deployed and the patients were discharged without experiencing any clinical events. The baseline clinical characteristics, baseline diameter stenosis and minimal luminal diameter were not different between the two groups. The follow-up diameter stenosis and late loss were significantly lower in the group I compared with group II (23.1 ± 12.7% vs. 47.3 ± 23.6%, p = 0.012; and 0.52 ± 0.26 mm vs. 1.12 ± 0.67 mm; p = 0.020, respectively). There were no TLR and MACE in group I; however the differences were not significant [0% (0/20) vs. 10.5% (2/19); p = 0.231 and 0% (0/20) vs. 15.8% (3/19), p = 0.106, respectively]. Conclusion: Carvedilol-eluting stents appear feasible to use and they may be effective in the prevention of coronary restenosis. These results warrant further confirmation with a large, randomized multi-center trial.

AB - Background and Objectives: Carvedilol is a beta- and alpha-receptor blocker, a direct inhibitor of smooth muscle cell proliferation and migration, and it produced a significant suppression of neointimal hyperplasia in our porcine experiment. The purpose of the study was to investigate the safety and efficacy of carvedilol-eluting BiodiVysio stent implantation for de novo lesions. Subjects and Methods: We performed a prospective randomized trial to compare two types of stents for revascularization in 39 patients [Group I (carvedilol-eluting stent): n = 20, 58.3 ± 11.1 years, and Group II (control stent): n = 19, 59.9 ± 8.5 years]. The primary effective end points were major adverse cardiac events (MACE): cardiac death, acute myocardial infarction, target lesion revascularization (TLR), in-stent restenosis and late lumen loss at the one-year clinical and angiographic follow-up. Results: All the stents were successfully deployed and the patients were discharged without experiencing any clinical events. The baseline clinical characteristics, baseline diameter stenosis and minimal luminal diameter were not different between the two groups. The follow-up diameter stenosis and late loss were significantly lower in the group I compared with group II (23.1 ± 12.7% vs. 47.3 ± 23.6%, p = 0.012; and 0.52 ± 0.26 mm vs. 1.12 ± 0.67 mm; p = 0.020, respectively). There were no TLR and MACE in group I; however the differences were not significant [0% (0/20) vs. 10.5% (2/19); p = 0.231 and 0% (0/20) vs. 15.8% (3/19), p = 0.106, respectively]. Conclusion: Carvedilol-eluting stents appear feasible to use and they may be effective in the prevention of coronary restenosis. These results warrant further confirmation with a large, randomized multi-center trial.

KW - Antioxidants

KW - Coronary disease

KW - Coronary restenosis

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=33646493407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646493407&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33646493407

VL - 36

SP - 115

EP - 120

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 2

ER -